Doris Duke Charitable Foundation 2019 Clinical Scientist Development Award, due annually in November

Pre-proposals due November 28, 2018 The Clinical Scientist Development Award consists of $150,000 annual direct costs plus $15,000 (10 percent) annual indirect costs for three years. The priority of the CSDA program is to fund outstanding individuals with potential for clinical research careers, whose projects will address highly significant research questions and lead to career advancement. DDCF does not have funding priorities based on disease area or research type.

Larissa Otero, MD, MPH receives K43 Emerging Global Leader Award, first investigator to receive the award in Latin America

Larissa Otero, MD, MPH, is an Assistant Professor and investigator at partner institution Universidad Peruana Cayetano Heredia (UPCH) and Instituto de Medicina Tropical Alexander von Humboldt (IMTAvH), in Lima, Peru. Dr. Otero was recently awarded the K43 Emerging Global Leader award from the Fogarty International Center (FIC) at the National Institutes of Health (NIH).

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection

The Centers for Disease Control and Prevention (CDC) released updated recommendations for use of once-weekly isoniazid-rifapentine for 12 weeks (3HP) for treatment of latent tuberculosis (TB) infection. The updated recommendations, published in CDC’s Morbidity and Mortality Weekly Report (MMWR), support expanded use of an effective, shorter, treatment regimen to reach even more people with latent TB infection. The updated recommendations include the use of 3HP:

Burroughs Wellcome Fund: Investigators in the Pathogenesis of Infectious Disease (PATH), due annually in July

July 16, 2018 : Pre-proposal deadline by Oct. 1, 2018 : Invitations sent Nov. 15, 2018 : Full application deadline The Investigators in the Pathogenesis of Infectious Disease (PATH) award provides $500,000 over five years to support accomplished investigators at the assistant professor level to study pathogenesis, with a focus on the interplay between human and microbial biology, shedding light on how human and microbial systems are affected by their encounters. Webinars will be held June 14, 18, and 26.

2018 TB Center Symposium: Cutting-Edge Translational Research in Tuberculosis, April 27, 2018

On Friday, April 27th the TB Center hosted the 2018 Symposium, "Cutting-Edge Translational Research in Tuberculosis". The symposium was attended by Vanderbilt faculty, staff, and students, as well as TN Department of Health and Metro Nashville Health Department members. We heard from a variety of speakers, who came from Nashville, Cincinnati, Seattle, and Brazil! Thomas Hawn, MD, PhD- "Macrophages and resistance to M.tuberculosis infection"

Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01/R21 Clinical Trial Not Allowed), expires: 05/08/2021

Application Due Date(s): Standard dates apply , by 5:00 PM local time of applicant organization. The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

Volunteer Opportunity in the Marshall Islands: TB+Leprosy Free Majuro

To the TB Community,The Republic of the Marshall Islands (RMI) Department of Health will soon begin an island-wide TB screening and treatment project. The goal is to identify, evaluate and treat both active and latent TB infection (LTBI) cases among adults and children living on Majuro Island. The 24-week project will take place between June and September this year, with follow-up and treatment teams continuing to work until November 16, 2018.